Announcements Trials

Browse Landscape

Phase

Phase 2 8 Phase 1/2 2 Phase 1 1

Status

Sponsor Class

INDUSTRY 5 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 416 Radiotherapy 276 fludarabine 238 Gemcitabine 211 Cisplatin 203 Nivolumab 184 pembrolizumab 183 Paclitaxel 176 Carboplatin 168 Magnetic Resonance Spectroscopy 166 fludarabine phosphate 156 Irinotecan 135 Bevacizumab 133 Cytarabine 128 Specimen Handling 124 Capecitabine 124 Temozolomide 123 Radiosurgery 118 Docetaxel 116 Biopsy 116 Ipilimumab 113 Dexamethasone 113 Radiation 111 Oxaliplatin 110 Fluorouracil 110 Rituximab 108 Etoposide 108 Filgrastim 99 Lenalidomide 98 Everolimus 96

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × OTHER × amivantamab × Clear all

NCT06632236 2025-04-25

5G-EMERALD

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡